Revance Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Revance Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-25.2%
Buyback Yield
| Total Shareholder Yield | -25.2% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Revance Therapeutics: Crown Merger Red Flags Makes For Problematic Call On Shares
Sep 26Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes
Jun 20What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You
Mar 04
Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain
Feb 29Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%
Dec 28Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be
Nov 10Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt
Aug 10Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors
Jun 14Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?
Apr 17Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt
Jan 02Revance Therapeutics submits sBLA for Daxxify for cervical dystonia
Oct 20Revance climbs 14% as FDA approves facial injectable for frown lines
Sep 08Revance Therapeutics: More Risk To Sept. 8 PDUFA Than It Seems
Aug 24Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?
Aug 04Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if RVNC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RVNC's dividend payments have been increasing.
Dividend Yield vs Market
| Revance Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (RVNC) | n/a |
| Market Bottom 25% (US) | 1.3% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Pharmaceuticals) | 2.4% |
| Analyst forecast (RVNC) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate RVNC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RVNC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate RVNC's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as RVNC has not reported any payouts.